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Exogenous administration of transforming growth factor-b (TGF-b) improves wound healing by affecting cellular
and molecular events involved in tissue repair. But mice with a deﬁciency of a key TGF-b signaling intermediate,
Smad3, paradoxically showed accelerated cutanenous wound healing, suggesting that endogenous Smad3 had
inhibitory effect on cutaneous wound healing. Here we investigated the effect of exogenous expression of Smad3
in dermal ﬁbroblasts on cutaneous wound healing. Subcutaneous injection of adenovirus-containing Smad3
complementary DNA (AdCMV-Smad3) targeting mainly dermal ﬁbroblasts accelerated tissue repair following full-
thickness dermal round wounds in rabbit ear as judged by the size of granulation tissue area, number of capillaries,
and re-epithelialization rate of the wounds. Expressions of a-smooth muscle actin (a-SMA), vascular endothelial
growth factor (VEGF), and ﬁbroblast growth factor receptor were upregulated in the wounded area injected with
AdCMV-Smad3. Consistent with the in vivo ﬁndings, overexpression of Smad3 induced a-SMA, VEGF, and TGF-b1
expression and augmented chemotactic response in cultured dermal ﬁbroblasts. Therefore, exogenous
administration of Smad3 targeting dermal ﬁbroblasts accelerated tissue repair in a rabbit dermal ulcer model by
affecting ﬁbroblast responses associated with wound healing. The results suggest that Smad3, when over-
expressed in dermal ﬁbroblasts, can promote wound healing.
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The wound healing is a multi-step complex process
consisting of inflammation, granulation tissue formation,
angiogenesis, re-epithelialization, and wound contraction
(Singer and Clark, 1999). When a full-thickness dermal
wound is made and filled by a fibrin clot, inflammatory cells
first migrate into the plasma clot and release local growth
factors, such as transforming growth factor-b (TGF-b),
platelet-derived growth factor (PDGF), and fibroblast growth
factor (FGF), which stimulate fibroblasts from the adjacent
intact dermis to migrate to the wounded site. The migrating
fibroblasts, along with newly formed vessels, fill the wound,
which results in the formation of granulation tissue.
Activated fibroblasts differentiate into myofibroblasts, a
subpopulation of specialized fibroblasts that express
a-smooth muscle actin (a-SMA), which elaborate collagen
and other matrix components and which eventually contract
the newly formed connective tissue to bring together the
edges of the wound, followed by re-epithelialization and
wound closes.
TGF-b is a multi-functional cytokine involved in cellular
proliferation, survival, differentiation, migration, and extra-
celluar matrix production (Massague, 1990). Numerous
evidence suggested that exogenous administration of
TGF-b into the skin accelerated wound healing, either
directly or indirectly, by stimulating recruitment of inflam-
matory cells, the production of extracellular matrix produc-
tion, the formation of new blood vessels, and wound
contraction (Sporn et al, 1983; Roberts, 1995). For instance,
the injection of TGF-b directly to the wound at the time of
wounding increased the healing rate accompanied by an
increased influx of mononuclear cells and fibroblasts and by
marked increases in collagen deposition at the site of
application of TGF-b in rats (Mustoe et al, 1987).
Recent investigation has revealed that the action of TGF-
b is mediated mainly by the Smad family of proteins (Heldin
et al, 1997; Attisano and Warana, 2000; Massague, 2000).
Activated TGF-b receptors phosphorylate the cytosolic
receptor-activated Smad2 and Smad3, which form hetero-
meric complexes with Smad4, and enter the nucleus, bind
to DNA, and regulate gene transcription in cooperation with
DNA binding cofactors. Inhibitory Smads, Smad6 and
Smad7, block TGF-b signal transduction, in part, by
preventing the interaction of Smad2/3 with the activated
TGF-b type I receptor.
In contrast to the prediction based on therapeutic effect
of ectopic TGF-b on wound healing, Smad3-deficient mice
showed accelerated wound healing associated with reduc-
tion of the influx of inflammatory cells and increased
re-epithelialization (Ashcroft et al, 1999), suggesting that
Abbreviations: a-SMA, a-smooth muscle actin; cDNA, comple-
mentary DNA; FGF, fibroblast growth factor; PDGF, platelet-derived
growth factor; TGF-b, transforming growth factor-b; VEGF, vascular
endothelial growth factor
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endogenous Smad3 functioned inhibitory for wound heal-
ing. In this study, we investigated the effect of exogenous
expression of Smad3 in dermal fibroblasts on cutaneous
wound healing using a rabbit dermal ulcer model.
Results
Adenovector-mediated in vivo gene transfer to the
skin To determine whether exogenous Smad3 regulated
wound healing, we examined the effect of exogenous
Smad3 or Smad7 for comparison on tissue repair in a rabbit
dermal ulcer model by using adenoviral-mediated skin gene
delivery. We have previously demonstrated the feasibility of
in vivo gene transfer to the skin mediated by replication-
deficient adenoviral vectors (Setoguchi et al, 1994b).
Consistent with the previous report, subcutaneous
injection of the adenovirus-containing lacZ cDNA (AdCMV-
lacZ) into the rabbit ear showed significant expression of
exogenous lacZ in the skin as judged by in situ b-galacto-
sidase staining 2 days after the injection (Fig 1A). In higher
magnification of the skin, the staining was observed largely
in cells with spindle morphology (fibroblasts) in the rabbit
dermis (Fig 1B).
Immunohistochemical studies with anti-Smad3 or anti-
Smad7 antibody showed that the expression of Smad3 or
Smad7 was detected on day 8 post-wounding after sub-
cutaneous injection of AdCMV-Smad3 or AdCMV-Smad7
(Fig 2). It should be noted that the antibodies used for
immunohistochemical detection of Smad3 or Smad7 failed
to detect endogenous Smad3 or Smad7, but detected only
overexpressed Smad3 or Smad7 after adenovirus infection
in the tissues.
Exogenous Smad3, but not Smad7, accelerates cuta-
neous wound healing in rabbits We then examined the
effect of in vivo gene transfer and expression of Smad3 or
Smad7 on tissue repair after full-thickness wounding on
rabbit ear. The amount of granulation tissue area, number of
capillary lumens in the granulation tissue, and degree of re-
epithelialization 8 days after the wounding were significantly
enhanced in the wounded skin injected with AdCMV-Smad3
when compared with those in the wounded skin injected
with AdCMV-lacZ (Fig 3). Interestingly, the injection of
AdCMV-Smad3 showed a level of the wound healing
equivalent to the application of total 1.5 mg of TGF-b1
(þAdCMV-lacZ) into the wounded skin. In contrast, the
number of capillary lumens in the granulation tissue and
degree of re-epithelialization 8 days after the incisional
wounding were significantly reduced in the wounded skin
injected with AdCMV-Smad7 when compared with those in
the wounded skin injected with AdCMV-lacZ (Fig 3).
Because histological evaluation revealed that the injec-
tion of AdCMV-Smad3 accelerated tissue repair in a rabbit
ulcer model, we next examined the effect of exogenous
Smad3 on cellular and molecular events involved in wound
healing. As shown in Fig 4, the number of a-smooth muscle
(a-SMA) positive cells (myofibroblasts) and expression of
VEGF and FGF receptors were strongly enhanced in the
wounded skin injected with AdCMV-Smad3 when com-
pared with the wounded skin injected with AdCMV-lacZ or
AdCMV-Smad7. Thus, accelerated healing of dermal ulcer
in a rabbit ear injected with AdCMV-Smad3 could be
attributed, at least in part, to increased number of
myofibroblast and increased expression of VEGF and FGF
receptor in the skin.
Overexpression of Smad3 induces a-SMA, VEGF,
and TGF-b1 expression and increases chemotactic
response in human dermal ﬁbroblasts in vitro Because
exogenous administration of Smad3 affected granulation
tissue formation, angiogenesis, and re-epithelialization in
vivo, we examined the effect of Smad3 overexpression on
several functions of dermal fibroblasts involved in wound
healing.
Human dermal fibroblasts were infected with AdCMV-
lacZ, AdCMV-Smad3, and AdCMV-Smad7 as previously
described (Sumiyoshi et al, 2003) and evaluated for a-SMA
expression, VEGF and TGF-b1 expression, and fibroblast
chemotaxis (Figs 5–7). We found that overexpression of
Smad3, but not lacZ or Smad7, strongly induced a-SMA
expression as shown by western blotting and immunofluor-
escence studies (Fig 5). Overexpression of Smad3 also
induced VEGF production (Fig 6A) and TGF-b1 expression
(Fig 6B). In addition, fibroblast chemotaxis was augmented
in human dermal fibroblasts overexpressing Smad3 when
compared with the cells overexpressing lacZ or Smad7 (Fig
7). These results suggested that overexpression of Smad3
was sufficient to express a-SMA, VEGF, and TGF-b1 and to
induce chemotactic response in dermal fibroblasts.
Figure 1
Expression of exogenous lacZ in rabbit skin. AdCMV-lacZ (5  108
pfu) was injected subcutaneously in the inner side of the ear. Two days
after the injection, the skin was evaluated for the presence of the lacZ
product (blue staining, b-galactosidase) using X-gal stain. Macroscopic
(A) and microscopic (B) pictures of the skin subcutaneously injected
with AdCMV-lacZ were shown. Please note that bgalactosidase
expression (blue staining) was observed in the injected skin area (A)
and interstitial spindle-like cells (B).
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Discussion
In this study, we showed that subcutaneous injection of
adenovirus-containing Smad3 cDNA into the rabbit ear
accelerated tissue repair following full-thickness dermal
wounds based on improvement of histological and cellular/
molecular parameters (Figs 3 and 4). Because subcuta-
neous injection of adenoviruses-containing Smads ap-
peared to target mainly dermal fibroblasts in our system
(Figs 1 and 2, Setoguchi et al, 1994b), the accelerated
wound healing by AdCMV-Smad3 could be, at least in part,
attributed to the effect of exogenous Smad3 on several
fibroblast functions involved in wound healing; that is,
myofibroblast differentiation (a-SMA expression), VEGF and
FGF receptors, and TGF-b1 expression, and chemotactic
response as shown in Figs 5–7.
Ashcroft et al (1999) reported that Smad3-deficient mice
showed accelerated cutaneous wound healing, suggesting
that endogenous Smad3 had inhibitory effect on cutaneous
wound healing. They suggested that downregulation of
inflammation and acceleration of re-epithelialization of
keratinocytes might contribute to the accelerated wound
healing in Smad3-deficint mice. In contrast, we found that
exogenous Smad3 resulted in increased granulation tissue
formation and re-epithelialization (Fig 3). In Smad3-deficient
mice, not only fibroblasts but also keratinocytes and
inflammatory cells are Smad3-deficient and they observed
net results of Smad3 deficiency in cutaneous wound
healing. In our study, however, main target cells were
dermal fibroblasts (Figs 1 and 2). Therefore, we think that
this study emphasizes the activity of TGF-b/Smad3 on
dermal fibroblast responses in the process of wound
healing and the difference of target cells may explain
different results in these studies. Alternatively, endogenous
deficiency of Smad3 throughout the development may
affect the cell function that is not attributed to the molecule
itself or even alter the function of cells that do not express
the molecule. This may also explain the different results in
these studies. In addition, it should be noted that re-
epithelialization in the whole wounded areas is usually
complete between days 15 and 20 post-wounding in this
dermal ulcer model in the rabbit ear and this study evaluate
early phase of cutaneous wound healing regarding re-
epithelialization.
Previous studies reported that dermal fibroblasts ex-
pressed a-SMA, VEGF, and FGF receptors in response to
TGF-b (Kikuchi et al, 1992; Desmouliere et al, 1993;
Pertovaara et al, 1994). Because in vivo expression of
a-SMA, VEGF, and FGF receptors after AdCMV-Smad3
injection appeared to be confined to the interstitial
fibroblast-like cells (Fig 4) and overexpression of Smad3
induced these molecules in human dermal fibroblasts
Figure 2
Expression of exogenous Smad3 or
Smad7 in wounded skin. AdCMV-
Smad3 (A and B) or AdCMV-Smad7 (C
and D) (5  108 pfu) was injected sub-
cutaneously in the inner side of the ear.
Two days after the injections, full-thick-
ness dermal round wounds were made in
the injected area. On 8 days after the
wounding, skin sections were immuno-
histochemically evaluated for the pre-
sence of Smad3 or Smad7 using
antibodies against these Smads. Pictures
after immunohistochemical stainings with
specific antibodies against Smad3 (A and
C) or against Smad7 (B and D) were
shown. Brown color indicates positive
staining. Please note that anti-Smad3
antibody showed immunoreactivity in the
skin sections injected with AdCMV-
Smad3 (A), but not with AdCMV-Smad7
(C). Please also note that anti-Smad7
antibody showed immunoreactivity in the
skin sections injected with AdCMV-
Smad7 (D), but not with AdCMV-Smad3
(B).
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in vitro (Figs 5 and 6), it is likely that, although TGF-b
activates multiple intracellular signaling pathways (Massa-
gue, 2000), ‘‘Smad3’’ is sufficient for mediating TGF-b-
induced expression of a-SMA, VEGF, and FGF receptors in
dermal fibroblasts both in vitro and in vivo.
TGF-b is a potent chemoattractant for human dermal
fibroblasts (Postlethwaite et al, 1987). Our findings that
overexpression of Smad3 in human dermal fibroblasts
enhanced chemotaxis (Fig 7) and increased granulation
tissue formation after AdCMV-Smad3 injection (Fig 3)
suggested that Smad3 mediated fibroblast chemotaxis
both in vitro and in vivo. It remains unclear, however,
whether Smad3, either directly or indirectly, stimulates
fibroblast chemotaxis in vivo.
We speculate that exogenous expression of Smad3 may
have some advantages over that of TGF-b for treatment of
cutaneous wounds. First, because we found that the effect
of AdCMV-Smad3 on cutaneous wound healing was
comparable with the effect of 1.5 mg exogenous TGF-b1
(Figs 3 and 4), exogenous expression of Smad3 may be
useful for treatment of cutaneous wounds without unfavor-
able systemic effect of TGF-b toward other organs or
systems such as tissue fibrosis and immune suppression.
Secondly, recent evidence suggests that chronic wounds
become unresponsiveness to growth factors including
PDGF and TGF-b (Hasan et al, 1997; Agren et al, 1999),
resulting in delayed or incomplete wound healing. For
instance, Kim et al (2003) reported that fibroblasts from
chronic wounds showed decreased TGF-b type II receptor
expression with their lack of response to TGF-b. Thus,
direct activation of intracellular TGF-b signaling by over-
expression of Smad3 may be a useful way for treatment of
chronic cutaneous wounds even if dermal fibroblasts in
wounded areas have altered TGF-b receptor expression
and lack of TGF-b response.
In summary, we showed that exogenous overexpression
of Smad3 in dermal fibroblasts promoted cutaneous wound
healing. Our findings suggest that modulation of Smad3
expression in dermal fibroblasts may have therapeutic
potential for the treatment of cutaneous wounds.
Materials and Methods
Adenovirus vector construction and virus puriﬁcation The
recombinant E1-deleted adenoviral vectors carrying mouse
Smad3, Smad7, or lacZ complementary DNA (cDNA) under
cytomegarovirus promoters, AdCMV-Smad3, AdCMV-Smad7, or
AdCMV-lacZ, were generated, purified, and transfected as
previously described (Setoguchi et al, 1994a; Fujii et al, 1999).
In situ b-galactosidase staining In situ b-galactosidase staining
was performed using in situ b-galactosidase staining kit (STRATA-
GENE) according to the manufacture’s instruction.
The rabbit ear dermal ulcer model Wounding design and sample
preparation were performed according to the previously reported
method (Tsuboi et al, 1995). Female white rabbits, 2.5–3.0 kg
(Shiraishi Laboratory Animals, Tokyo, Japan) were anesthetized
Figure3
Acceleration of cutaneous wound healing by exogenous Smad3,
but not Smad7. AdCMV-lacZ, AdCMV-Smad3, or AdCMV-Smad7 was
subcutaneously injected into rabbit skin. Two days after the injections,
full-thickness dermal round wounds were made in the injected area
with or without application of TGF-b1 as indicated. Eight days after the
wounding, skin sections were microscopically evaluated by HE staining
(A) and by quantitative analysis of granulation tissue area (B), the
number of capillaries (C), and re-epithelialization rate (D) as described
in the Materials and Methods. Please note that injection of AdCMV-
Smad3 enhanced granulation tissue area (B), the number of capillaries
(C), and re-epithelialization rate as compared with injection of AdCMV-
lacZ. The arrow in figure A lacZ picture indicates the wounded area in
rabbit skin.
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with xylazine hydrochloride solution (10 mg per kg) (Bayer Co.,
Leverkusen, Germany) and ketamine hydrochloride solution (30 mg
per kg) (Sankyo Co., Tokyo, Japan). After sterilization with iodine
and alcohol, 5  108 plaque-forming units (pfu) of AdCMV-lacZ,
AdCMV-Smad3, or AdCMV-Smad7 were injected subcutaneously
in the inner side of the rabbit ear. The doses and timing of the
adenovirus injection were determined according to our previous
study (Setoguchi et al, 1994b). Forty-eight hours after the
injections, four full-thickness round wounds were prepared on
the injected area using a calibrated 6 mm trephine (Acu Punch,
Acuderm Inc., Lauderdale, Florida) under sterile conditions (day 1).
The perichondrium was kept undamaged. The wounds were
covered with a sterilized transparent dressing (Tegaderm, 3M,
Tokyo, Japan), and 20 mL PBS or 20 mL recombinant human TGF-
b1 (R&D, Minnesota) solution (25 ng per mL: 500 ng per one ulcer)
was applied to each wound using a syringe once every other day
until the 5th day (on day 1, 3, and 5; total 1.5 mg per one ulcer). The
ear was bandaged and kept covered throughout the experiment.
The rabbits were killed on the 8th day after the wounding by
intravenous administration of pentobarbital solution. The wounded
areas were excised and fixed in 10% buffered formalin solution. All
animal experiments were performed according to the approved
manual of the Institutional Review Board of Juntendo University.
Histological evaluation After overnight fixation, the tissue was
trimmed and cut through at the widest margin. The tissue was
embedded in paraffin and sectioned in 5 mm increments. The
sections were made perpendicular to the anterior–posterior axes
and perpendicular to the surface of the wound. Three sections
were placed on a slide, and stained with hematoxylin and eosin. Of
the three sections on any one slide, the section with the widest
original wound margin was used for assessment. The parameters
measured were degree of granulation tissue area, number of
capillaries, and re-epithelialization as previously described (Tsuboi
et al, 1995). Each of the parameters was graded numerically as
described below.
Granulation tissue area The amount of granulation tissue was
quantified by measuring the area of granulation tissue (mm2) in the
section perpendicular to the surface of the wound. Granulation
tissue was traced by a computerized morphometric analysis (KS-
400, Carl Zeiss Inc., Gotingen, Germany).
Figure 4
Induction of a-SMA, VEGF, and FGF receptor expression by exogenous Smad3 in wounded skin. AdCMV-lacZ, AdCMV-Smad3, or AdCMV-
Smad7 was subcutaneously injected into rabbit skin. Two days after the injections, full-thickness dermal round wounds were made in the injected
area with or without application of TGF-b1 as indicated. Eight days after the wounding, skin sections were immunohistochemically stained with
antibodies specific for a-SMA (A), VEGF (B), and FGF receptor (C). Brown color indicates the positive staining. Please note that injection of AdCMV-
Smad3 enhanced a-SMA (A), VEGF (B), and FGF receptor (C) expression (brown color) in the wounded skin.
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Number of capillaries The number of capillary lumens in the
granulation tissue was counted in the complete wound cross-
section at  100 magnification.
Re-epithelialization The degree of re-epithelialization was mea-
sured by a computerized morphometric analysis (KS-400) and was
given a value by percentage; 0% was equivalent to no closure and
100% was equivalent to complete wound closure.
Immunohistochemistry Skin paraffin sections were deparaffi-
nized and then preincubated with normal mouse or goat serum
(1:20) for 20 min. The slides were incubated overnight at 41C with
mouse monoclonal antibody against vascular endothelial growth
factor (VEGF) (05-443, Upstate Biotechnology, Lake Placid, New
York 1:50) or mouse monoclonal antibody against FGF receptor
(MAB125, CHEMICON, Temecula, California 1:150), goat poly-
clonal antibody against Smad3 (sc-6202, Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, California 1:100), mouse monoclonal
antibody against a-SMA (U7033, DAKO EPOS, 1:1), or goat
polyclonal antibody against Smad7 (sc-7004, Santa Cruz Biotech-
nology, Inc., 1:100). Sections were then incubated for 60 min at
room temperature with an Envision labeled polymer reagent
(K1490, DAKO, Glostrup, Denmark). To increase their sensitivity,
sections were then incubated for 10 min at room temperature with
a Tyramide signal amplification (TSA) Biotin System (NEN life
science products, Boston, Texas, 1:50). Sections were then
incubated with a streptavidin (DAKO, 1:400) for 30 min. Between
steps, the slides were rinsed for 10 min in PBS. All sections were
lightly counterstained with hematoxylin.
Cell culture Primary human dermal fibroblasts were cultured as
previously described (Lee et al, 1996). Briefly, fibroblasts were
obtained from the outgrowth of infant foreskin and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS) and 100 mg per mL streptomycin. All
experiments were carried out using fibroblasts in passage 4–8th.
Infection of recombinant adenoviruses was performed at a multi-
plicity of infection (m.o.i.) of 2  102 pfu per cell in 1 mL of serum-
free DMEM for 60 min and overexpression of exogenous Smad3 or
Smad7 in the cultured human dermal fibroblasts after the
transfection was previously reported (Sumiyoshi et al, 2003).
Dermal fibroblasts infected with the adenovirus solutions were
cultured in DMEM supplemented with 10% FCS for 48 h and
thereafter used for the following experiments.
Immunoblot Immunoblotting with anti-a-SMA antibody (American
Research Product, Belmont, Massachusetts 1:500) was performed
as previously described (Nakao et al, 1997).
Immunoﬂuorescence microscopy Dermal fibroblasts infected
with the adenovirus solutions were grown on rat tail collagen type
I-coated eight well culture slides (Beckton Dickinsons Labware,
Bedford, Massachusetts) in the absence or presence of TGF-b1
(10 ng per mL) (R&D, Minnesota) for 24 h, then washed with
PBS and fixed with 4% paraformaldehyde. Following permeabili-
zation, slides were stained with anti-a-SMA antibody (American
Research Product, 1:3) diluted in PBS 90 min at room temperature.
After extensive washing, slides were incubated with Alexa488-
conjugated goat anti-mouse antibody (1:200) for 1 h at room
temperature. After extensive washing, slides were incubated with
DAPI solution (100 ng per mL) for 5 min. Fibroblasts were mounted
in fluorescent mounting medium (DAKO), and images were
acquired using a confocal microscopy (ECLIPSE E800, Nikon,
Japan).
Figure5
Induction of a-SMA by overexpression
of Smad3 in human dermal fibroblasts.
Cultured human dermal fibroblasts in-
fected with adenoviruses carrying lacZ,
Smad3, or Smad7 cDNA were incubated
with 0.5 (A) or 10 ng per mL (B) of TGF-b1
for 24 h. Then, western blot analysis (A) or
immunofluorescence anlayisis with anti-a-
SMA antibody followed by incubation with
Alexa488-conjugated secondary antibody
(Green staining) (B) was performed. Nu-
cleus was stained with DAPI solution
(Blue staining). Similar results were ob-
tained in at least three independent
experiments. Please note that overex-
pression of Smad3 in dermal fibroblasts
enhanced a-SMA expression as judged
by western blotting (A) and immunofluor-
escence study (B).
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Migration assay Migration assay was performed using quantita-
tive cell migration assay kit (ECM500, Chemicon International Inc.)
according to the manufacture’s instruction.
Cytokine ELISA The amount of VEGF in the culture supernatant
of fibroblasts was determined using human VEGF ELISA kit (R&D,
Minnesota).
RT-PCR Total RNA was prepared from cultures of dermal
fibroblasts 72 h after the infection of adenoviruses carrying lacZ,
Smad3, and Smad7, as recommended by manufacture’s instruc-
tions for Isogen solution (Nippon Gene, Japan). cDNA was
synthesized from 3 mg of total RNA using first strand cDNA
synthesis kit (Ready To Go) (Amersham Pharmacia, Piscataway,
New Jersey). PCR amplification (951C for 1 min, 581C for 2 min,
and 721C for 2 min; 25 cycles) was performed in a DNA thermal
cycler (Perkin-Elmer, Wellesley, Massachusetts). The PCR pro-
ducts were size-fractionated by agarose gel electrophoresis using
2.0% agarose, and stained with 0.5 mg per mL ethidium bromide.
As positive controls, we used expression constructs of human
TGF-b1 cDNA. Primers used in this study were as follows: TGF-b1
(50-AGTATGGACACAGGCTCTCC-30 and 30-GTCTTATGGCTTCC-
GTCTG-50), and hypoxanthine phosphoribosyltransferase (HPRT)
(50-TTCTTTGCTGACCTGCTG-30 and 30-TTTCTACCAGTTCCAG-
CG-50).
Data analysis Data are summarized as mean  SD. Statistical
analysis was performed using the unpaired Student t test. po0.05
was considered to be significant.
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